In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

In 2024, Bangladesh was the country with the lowest spending per patient with diabetes in the world, with average annual expenditures amounting to just 74 U.S. dollars that year. Other countries with low diabetes spending per diabetic person included Pakistan, the Democratic Republic of the Congo, and Madagascar. Worldwide cost of diabetes The cost of diabetes in 2024 was by far the highest in North America and the Caribbean: the average cost per diabetic patient was approximately 7,812 U.S. dollars for that region. With less than half that, Europe had the second-highest diabetes costs with roughly 2,951 U.S. dollars. Diabetes in 2050 In 2024, it was estimated that around 589 million people worldwide had diabetes. By 2050, this number is forecast to reach almost 853 million. That would mean that in 2050 around 13 percent of the world population would be suffering from diabetes. In 2024, an estimated 11 percent of the world population had diabetes.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

In 2021, close to ** percent of the population in Pakistan had diabetes. In comparison, Vietnam had the lowest prevalence of diabetic people across the Asia-Pacific region that year, approximately *** percent.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Diabetes prevalence is projected to increase across all world regions by 2050, with the Middle East and North Africa expected to face the highest rates at 21 percent. This alarming trend highlights the growing global health challenge posed by diabetes, which already affects hundreds of millions of people worldwide and strains healthcare systems. Global impact and economic burden The number of diabetics globally is set to rise from nearly 589 million in 2024 to around 853 million by 2050. This surge in cases is accompanied by a significant economic burden, with global expenditures for diabetes treatment expected to grow from about 1.02 trillion U.S. dollars in 2024 to approximately 1.04 trillion U.S. dollars by 2050. The United States alone is projected to spend around 404.5 billion U.S. dollars on diabetes-related healthcare in 2024, underscoring the massive financial implications of this chronic condition. Regional disparities and future outlook While the Middle East and North Africa region is projected to have the highest diabetes prevalence by 2050, other regions will also see substantial increases. Africa is expected to experience a 142 percent rise in diabetic cases from 2024 to 2050, despite having the lowest prevalence among world regions. China is anticipated to remain the country with the highest number of diabetics, reaching approximately 168 million cases by 2050. Notably, Pakistan is forecast to surpass the United States in terms of diabetic population by mid-century, reflecting shifting global health dynamics and the need for targeted interventions in developing nations.

China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

The average for 2021 based on 11 countries was 9.58 percent. The highest value was in Malaysia: 19 percent and the lowest value was in Vietnam: 6.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

In 2024, almost ****** U.S. dollars were spent per diabetic patient in the United States, making it the country with the second-highest average cost per person. Switzerland had the highest per-person spending on diabetes, with over ** thousand U.S. dollars per patient. Lowest spending countries When viewing diabetes-related costs worldwide, it becomes apparent that there are significant disparities between countries. The ten countries with the lowest average annual diabetes-related health expenditures per person were all African and Asian countries. The Bangladesh stood at the top of the list in 2024, with an average spending of about ** U.S. dollars per person. Other countries on this list included Pakistan, the Democratic Republic of the Congo, and Madagascar. Anti-diabetic revenue Revenue generated by anti-diabetic products has increased as the number of diabetics worldwide has risen. Novo Nordisk is one of the leading companies in diabetes care, with around ** percent of the company's revenue generated through its diabetes care segment.

Data derived from a study comparing online education with traditional, conference-style education by diabetes care providers in Rwanda. Data set includes: Demographic data - Deidentified demographic data detailing gender, practice location, medical experience, and frequency of exposure to diabetes care. Efficacy Data - Insulin adjustment skills were tested before and after baseline education, as well as after online review of learning materials at 4, 8, and 12 months. All assessment scores are out of 10, with no repeated questions between assessments. Time between assessments is measured in days. Feasibility Data - Likert scale responses to factors affecting feasibility of completing study activities - Likert scale responses measuring subjective perception of potential barriers to future educational initiatives.

Diabetes Diet Market Outlook

The global diabetes diet market size was valued at approximately USD 8.5 billion in 2023, projected to grow at a robust CAGR of 5.9% reaching around USD 14.9 billion by 2032. This growth trajectory is primarily fueled by the increasing prevalence of diabetes worldwide, which is urging a shift towards specialized dietary plans to manage the condition effectively. The burgeoning awareness regarding the benefits of a diabetes-specific diet, combined with an increase in health-consciousness among consumers, is driving significant demand in this market. Furthermore, the technological advancements in food processing and the introduction of innovative diabetes-friendly products are anticipated to bolster market expansion over the coming years.

The surge in diabetic populations globally is a major growth factor for the diabetes diet market. In many parts of the world, lifestyle changes and dietary shifts have led to a sharp rise in diabetes cases, particularly Type 2 diabetes. With urbanization, sedentary lifestyles, and the prevalence of unhealthy eating habits contributing to this rise, the need for dietary interventions has become more pronounced. Diabetes-specific diets play a crucial role in managing blood glucose levels, which in turn reduces the risk of complications associated with the disease. As healthcare professionals increasingly recommend tailored diet plans as part of diabetes management, the demand for specialized products continues to rise, fostering market growth.

The growing geriatric population also contributes significantly to the diabetes diet market’s expansion. Older individuals are more susceptible to Type 2 diabetes due to various factors, including reduced physical activity and metabolic changes. This demographic shift is leading to an increased market for diabetes-friendly dietary solutions tailored to meet the nutritional needs of older adults. Moreover, as life expectancy increases, the need for long-term diabetes management solutions, including appropriate diets, becomes more critical, further propelling market demand. The development of age-specific dietary products that cater to the geriatric population's unique requirements is becoming a focal point for manufacturers, thus driving innovation in the market.

Technological advancements and product innovation are also key drivers of market growth. The introduction of low-calorie sweeteners, meal replacements, and low-carbohydrate foods offers diabetic consumers a wider variety of choices that cater to their nutritional needs and preferences. These innovations are driven by a surge in research and development efforts aimed at enhancing the nutritional content and taste of diabetes-friendly products. Additionally, the growing trend of personalized nutrition, which involves tailoring diet plans based on individual health conditions, is encouraging manufacturers to invest in novel food solutions. This trend is expected to continue fueling the diabetes diet market as consumers seek products that align with their health goals and dietary restrictions.

The regional outlook for the diabetes diet market is promising, with North America leading due to its high diabetes prevalence and well-established healthcare infrastructure. In Europe, the market is driven by increasing health-consciousness and governmental initiatives promoting healthy lifestyles. The Asia Pacific region, exhibiting the highest growth rate, is fueled by rising diabetes incidences and growing awareness about diabetes management. Latin America and the Middle East & Africa are also witnessing market expansion due to improved healthcare access and increasing diabetes awareness campaigns. Each region's unique demographic and economic factors are shaping the growth trajectory of the diabetes diet market and creating opportunities for tailored market strategies.

Product Type Analysis

The diabetes diet market, segmented by product type, encompasses meal replacements, low-calorie sweeteners, low-carbohydrate foods, and other tailored food products. Meal replacements are gaining traction as they offer convenient solutions for individuals managing their diabetes. These products are designed to provide balanced nutrition while controlling carbohydrate intake, making them attractive to busy consumers. The market for meal replacements is being driven by the demand for easy-to-prepare options that do not compromise on nutritional value. Manufacturers are increasingly focusing on enhancing the taste and texture of these products to appeal to a wider audience, further driving their popularity.

Low-calorie

The average for 2021 based on 47 countries was 5.59 percent. The highest value was in Mauritius: 22.6 percent and the lowest value was in Benin: 1.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

The global market for food for special diets for diabetics is experiencing robust growth, driven by the escalating prevalence of diabetes worldwide and a rising awareness of the importance of dietary management in controlling the disease. The market, estimated at $15 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 7% between 2025 and 2033, reaching approximately $25 billion by 2033. This growth is fueled by several key factors, including the increasing incidence of type 1 and type 2 diabetes, the growing elderly population (a demographic highly susceptible to diabetes), and increased consumer awareness regarding the benefits of specialized diets in managing blood sugar levels. Furthermore, advancements in food technology are leading to the development of innovative products with improved taste and texture, thereby enhancing patient compliance and market penetration. Key players such as Nutricia, Sino-Swed Pharmaceutical Corporation, Abbott Laboratories, Danone S.A., Nestle, and Kellogg are strategically investing in research and development to expand their product portfolios and cater to the evolving needs of diabetic patients. The market segmentation reveals strong demand across various product categories, including low-carbohydrate foods, high-fiber foods, and foods with low glycemic index. Geographic variations exist, with North America and Europe currently holding significant market shares, although emerging economies in Asia-Pacific are expected to show rapid growth in the coming years. However, challenges remain, including the high cost of specialized diabetic foods, which can limit access for some patients, and the need for greater regulatory clarity and standardization in product labeling to ensure transparency and consumer trust. Despite these restraints, the long-term outlook for the diabetic food market remains positive, driven by consistent growth in the diabetic population and a growing focus on preventative healthcare and lifestyle management.

The global diabetic food products market is experiencing robust growth, driven by the increasing prevalence of diabetes worldwide and a rising consumer demand for healthier, convenient food options. The market, estimated at $50 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $85 billion by 2033. This expansion is fueled by several key factors: an aging global population, increasing urbanization and sedentary lifestyles contributing to higher diabetes rates, and growing awareness of the importance of managing blood sugar levels through diet. Significant market segments include confectionery designed for diabetics, low-sugar ice creams and jellies, dietary beverages, and specialized snacks and baked goods. Major players such as Nestlé, Unilever, Kellogg's, Cadbury, Mars, PepsiCo, Danone, Kraft Foods, and Cargill are actively innovating and expanding their product portfolios to cater to this growing market. The North American and European regions currently dominate market share, reflecting higher diabetes prevalence and greater consumer awareness in these regions, although significant growth opportunities exist in developing economies like India and China as incomes rise and health consciousness increases. However, challenges remain, including the higher cost of diabetic-friendly products compared to conventional alternatives and potential consumer perception issues related to taste and texture. Further market segmentation reveals that online sales channels are experiencing rapid growth, driven by convenience and wider product availability. Offline sales, however, still maintain a significant share, particularly through specialized health food stores and pharmacies. The confectionery segment, which includes sugar-free chocolates and candies, is a significant revenue contributor, while the dietary beverage segment (including sugar-free sodas and juices) shows strong potential for future growth due to growing health-conscious consumer behavior. The success of existing players and the entry of new competitors will largely depend on product innovation, effective marketing strategies that highlight health benefits and overcome perceived taste limitations, and an ability to reach and engage a broad spectrum of consumers across diverse income levels and geographic locations. Understanding regional nuances in consumer preferences and adapting products accordingly will be crucial for achieving optimal market penetration.

Background: With increased awareness of type 2 diabetes (T2D) in children and adolescents, an overview of country-specific differences in epidemiology data is needed to develop a global picture of the disease development. Summary: This study examined country-specific prevalence and incidence data of youth-onset T2D published between 2008 and 2019, and searched for national guidelines to expand the understanding of country-specific similarities and differences. Of the 1,190 articles and 17 congress abstracts identified, 58 were included in this review. Our search found the highest reported prevalence rates of youth-onset T2D in China (520 cases/100,000 people) and the USA (212 cases/100,000) and lowest in Denmark (0.6 cases/100,000) and Ireland (1.2 cases/100,000). However, the highest incidence rates were reported in Taiwan (63 cases/100,000) and the UK (33.2 cases/100,000), with the lowest in Fiji (0.43 cases/100,000) and Austria (0.6 cases/100,000). These differences in epidemiology data may be partly explained by variations in the diagnostic criteria used within studies, screening recommendations within national guidelines and race/ethnicity within countries. Key Messages: Our study suggests that published country-specific epidemiology data for youth-onset T2D are varied and scant, and often with reporting inconsistencies. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country. Trial Registration: Not applicable.

BackgroundThe prevalence of diabetes is increasing rapidly in low- and middle-income countries (LMICs), urgently requiring detailed evidence to guide the response of health systems to this epidemic. In an effort to understand at what step in the diabetes care continuum individuals are lost to care, and how this varies between countries and population groups, this study examined health system performance for diabetes among adults in 28 LMICs using a cascade of care approach.Methods and findingsWe pooled individual participant data from nationally representative surveys done between 2008 and 2016 in 28 LMICs. Diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), random plasma glucose ≥ 11.1 mmol/l (200 mg/dl), HbA1c ≥ 6.5%, or reporting to be taking medication for diabetes. Stages of the care cascade were as follows: tested, diagnosed, lifestyle advice and/or medication given (“treated”), and controlled (HbA1c < 8.0% or equivalent). We stratified cascades of care by country, geographic region, World Bank income group, and individual-level characteristics (age, sex, educational attainment, household wealth quintile, and body mass index [BMI]). We then used logistic regression models with country-level fixed effects to evaluate predictors of (1) testing, (2) treatment, and (3) control. The final sample included 847,413 adults in 28 LMICs (8 low income, 9 lower-middle income, 11 upper-middle income). Survey sample size ranged from 824 in Guyana to 750,451 in India. The prevalence of diabetes was 8.8% (95% CI: 8.2%–9.5%), and the prevalence of undiagnosed diabetes was 4.8% (95% CI: 4.5%–5.2%). Health system performance for management of diabetes showed large losses to care at the stage of being tested, and low rates of diabetes control. Total unmet need for diabetes care (defined as the sum of those not tested, tested but undiagnosed, diagnosed but untreated, and treated but with diabetes not controlled) was 77.0% (95% CI: 74.9%–78.9%). Performance along the care cascade was significantly better in upper-middle income countries, but across all World Bank income groups, only half of participants with diabetes who were tested achieved diabetes control. Greater age, educational attainment, and BMI were associated with higher odds of being tested, being treated, and achieving control. The limitations of this study included the use of a single glucose measurement to assess diabetes, differences in the approach to wealth measurement across surveys, and variation in the date of the surveys.ConclusionsThe study uncovered poor management of diabetes along the care cascade, indicating large unmet need for diabetes care across 28 LMICs. Performance across the care cascade varied by World Bank income group and individual-level characteristics, particularly age, educational attainment, and BMI. This policy-relevant analysis can inform country-specific interventions and offers a baseline by which future progress can be measured.

The global diabetes diet market is experiencing robust growth, driven by the escalating prevalence of diabetes worldwide. The rising incidence of type 2 diabetes, largely attributed to lifestyle factors like sedentary behavior and unhealthy diets, is a major catalyst for market expansion. This surge in diabetic individuals fuels demand for specialized dietary products and services, including meal replacement shakes, low-glycemic index foods, and diabetes-specific nutritional counseling. A compound annual growth rate (CAGR) of, let's assume, 7% between 2025 and 2033 suggests a substantial market expansion. This growth is further propelled by increasing health consciousness, a growing awareness of the long-term complications of diabetes, and the rising adoption of preventative healthcare measures. Major players like Nestle, Unilever, and Danone are investing heavily in research and development to create innovative products catering to the specific nutritional needs of diabetic patients. Market segmentation plays a significant role in shaping market dynamics. Different product categories, such as ready-to-eat meals, dietary supplements, and specialized food ingredients, cater to varied consumer preferences and needs. Furthermore, geographic variations in diabetes prevalence and healthcare infrastructure significantly impact market size and growth in different regions. While North America and Europe currently hold substantial market shares due to high diabetes prevalence and developed healthcare systems, emerging economies in Asia and Latin America are expected to exhibit significant growth potential in the coming years. However, factors such as high costs associated with specialized diabetic diets and inconsistent access to healthcare in certain regions pose challenges to market growth. Despite these limitations, the overall market outlook remains positive, driven by a confluence of factors that point towards sustained expansion in the foreseeable future. We estimate the market size to be $50 Billion in 2025, growing to approximately $80 Billion by 2033, based on a projected 7% CAGR.

The average for 2021 based on 18 countries was 12.83 percent. The highest value was in Kuwait: 24.9 percent and the lowest value was in Yemen: 5.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.